US 11,944,616 B2
Dizocilpine derivatives as peripheral NMDA receptor antagonists
Sylvia Cohen-Kaminsky, Le Plessis-Robinson (FR); Marc Humbert, Le Plessis-Robinson (FR); Sebastien Dumas, Le Plessis-Robinson (FR); Gilles Bru-Mercier, Le Plessis-Robinson (FR); Samir Messaoudi, Chatenay-Malabry (FR); Jean-Daniel Brion, Chatenay-Malabry (FR); Mouad Alami, Chatenay-Malabry (FR); and Gilles Galvani, Chatenay-Malabry (FR)
Assigned to INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITÉ PARIS-SACLAY, Saint Aubin (FR); ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), Paris (FR); and HOPITAL MARIE LANNELONGUE, Le Plessis-Robinson (FR)
Filed by INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICAL (INSERM), Paris (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR); UNIVERSITÉ PARIS-SACLAY, Saint Aubin (FR); ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), Paris (FR); and HOPITAL MARIE LANNELONGUE, Le Plessis-Robinson (FR)
Filed on May 26, 2022, as Appl. No. 17/825,082.
Application 17/825,082 is a division of application No. 16/308,654, granted, now 11,376,245, previously published as PCT/EP2017/064409, filed on Jun. 13, 2017.
Claims priority of application No. 16305712 (EP), filed on Jun. 13, 2016.
Prior Publication US 2022/0280498 A1, Sep. 8, 2022
Int. Cl. C07D 471/08 (2006.01); A61K 31/439 (2006.01); A61K 31/46 (2006.01); A61K 45/06 (2006.01); A61P 9/12 (2006.01); C07D 451/00 (2006.01); C07D 451/02 (2006.01)
CPC A61K 31/46 (2013.01) [A61K 45/06 (2013.01); A61P 9/12 (2018.01); C07D 451/00 (2013.01); C07D 451/02 (2013.01)] 14 Claims
 
1. Compound of formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 represents a cyclobutyl group;
R2 represents a (C1-C10)alkyl group;
n is 1;
R3, R4, R5, R6, R7, R8, R9 and R10 represent a hydrogen atom; and X− is an anionic counterion selected from the group consisting of I−, Cl−, Br−, and OH−.